Acharya UR, Ng EYK, Tan JH, Sree SV.Thermography based breast cancer detection usingtexture features and supportvector machine. J MedSyst. 2012;36(3):1503-10.2.Haghbeen M, Tayer AH, Kamravan M, Jahromi AS.Derived Procoagulant Microparticles as Blood-BasedBiomarker of Breast Cancer. Asian Pac J Cancer Prev.2021;22(5):1573.3.Timp JF, Braekkan SK, Versteeg HH, CannegieterSC. Epidemiology of cancer-associated venousthrombosis. Blood. 2013;122(10):1712-23.4.Hisada Y, Geddings J, Ay C, Mackman N. Venousthrombosis and cancer: from mouse models to clinicaltrials. J Thromb Haemost. 2015;13(8):1372-82.5. Levitan N, Dowlati A, Remick SC, Tahsildar HI,Sivinski LD, Beyth R, et al. Rates of initial andrecurrent thromboembolic disease among patientswith malignancy versus those without malignancy.Risk analysis using Medicare claims data. Medicine(Baltimore). 1999;78(5):285-91.6.Hisada Y, Mackman N. Cancer-associated pathwaysand biomarkers of venous thrombosis. Blood.2017;130(13):1499-506.7.Walker AJ, West J, Card TR, Crooks C, Kirwan CC,Grainge MJ. When are breast cancer patients athighest risk of venous thromboembolism? A cohortstudy using English health care data. Blood.2016;127(7):849-57.8.Vader P, Breakefield XO, Wood MJ. Extracellular
vesicles: emerging targets for cancer therapy. TrendsMol Med. 2014;20(7):385-93.9.Muralidharan-Chari V, Clancy JW, Sedgwick A,D'Souza-Schorey C. Microvesicles: mediators ofextracellular communication during cancerprogression. J Cell Sci. 2010;123(10):1603-11.10.Berghuis AS, Koffijberg H, Prakash J, TerstappenLW, IJzerman MJ. Detecting blood-based biomarkersin metastatic breast cancer: a systematic review oftheir current status and clinical utility. Int J Mol Sci.2017;18(2):363.11.Welsh J, Smith J, Yates K, Greenman J, MaraveyasA, Madden L. Tissue factor expression determinestumour cell coagulation kinetics. Int J Lab Hematol.2012;34(4):396-402.12.Chang W, Fa H, Xiao D, Wang J. Targetingphosphatidylserine for Cancer therapy: prospects andchallenges. Theranostics. 2020;10(20):9214.13.Tayer AH, Amirizadeh N, Ahmadinejad M,Nikougoftar M, Deyhim MR, Zolfaghari S.Procoagulant activity of red blood cell-derivedmicrovesicles during red cell storage. Transfus MedHemother. 2019;46(4):224-30.14.Zhang C, Yang Z, Zhou P, Yu M, Li B, Liu Y, et al.
Phosphatidylserine-exposing tumor-derivedmicroparticles exacerbate coagulation and cancer celltransendothelial migration in triple-negative breastcancer. Theranostics. 2021;11(13):6445.15.Aharon A, Sabbah AR, Issman L, Berkovich H,
Copty R, Talmon Y, et al. Effects of low-and high-dose chemotherapy agents on thrombogenicproperties of extracellular vesicles derived from breastcancer cell lines. J Thromb Haemost.2018;118(03):480-9.16.Trappenburg MC, van Schilfgaarde M, BredewoldEO, van Aalderen MC, Spronk HM, Ten Cate H, et al.Elevated numbers and altered subsets of procoagulant
microparticlesin breast cancer patients usingendocrine therapy. Thromb Res. 2011;127(4):363-9.17.Aharon A, Sabbah A, Ben-Shaul S,Berkovich H,Loven D, Brenner B, et al. Chemotherapyadministration to breast cancer patients affects
extracellular vesicles thrombogenicity and function.Oncotarget. 2017;8(38):63265.18. Lima LG, Monteiro RQ. Activation of bloodcoagulation in cancer: implications fortumourprogression. Biosci Rep. 2013;33(5):e00064.19. Rautou PE, Mackman N. Microvesicles as riskmarkers for venous thrombosis. Expert Rev Hematol.2013;6(1):91-10120.Geddings JE, Hisada Y, BoulaftaliY,Getz TM,WhelihanM,Fuentes R,etal. Tissue factor–positivetumor microvesicles activate platelets and enhancethrombosis in mice. J Thromb Haemost.2016;14(1):153-66.21.Hron G, Kollars M, Weber H, Sagaster V,Quehenberger P, Eichinger S, et al. Tissue factor-positive microparticles: cellular origin and associationwith coagulation activation in patients with colorectalcancer. J Thromb Haemost. 2007;97(1):119-23.22.Zwicker JI, Liebman HA, Neuberg D, Lacroix R,Bauer KA, Furie BC, et al. Tumor-derived tissuefactorbearing microparticles are associated with
venous thromboembolic events in malignancy. ClinCancer Res. 2009;15(22):6830-40.23.Bourcy M, Suarez-Carmona M, LambertJ,FrancartM-E,SchroederH, Delierneux C, et al. Tissue FactorInduced by Epithelial–Mesenchymal TransitionTriggers a Procoagulant State That Drives Metastasisof Circulating Tumor CellsEMT-Induced TF andProcoagulant Properties of CTCs. Cancer Res.2016;76(14):4270-82.24.Yu Y, Böing AN, Hau CM, Hajji N, Ruf W, Sturk A,et al. Tissue factor coagulant activity is regulated bythe plasma membrane microenvironment. J ThrombHaemost. 2018;118(06):990-1000.25. Van der Pol E, Van Gemert MJ, Sturk A, NieuwlandR, Van Leeuwen TG. Single vs. swarm detection ofmicroparticles and exosomes by flow cytometry. JThromb Haemost. 2012;10(5):919-30.
مجله علوم پزشکی پارس